| Aging is linked to reduced GABA production and gut microbiota changes, impacting metabolism
and immunity. We hypothesize that a GABA-producing probiotic will enhance immune function
and alter the metabolic profile of aging mice. This intervention may also improve intestinal barrier
integrity and reduce inflammation, offering antiaging benefits. Declining gut lactic acid bacteria
(LAB) and GABA levels may contribute to unhealthy aging and immune-related diseases. In our
current study, we introduce the Lactococcus lactis strain IL1403 and Lactococcus lactis-P8s-GAD,
a genetically engineered probiotic into the adult rats that increases the production of GABA in the
gut and considered the subsequent impact on the microbial diversity through 16S rRNA sequencing,
and developed proteomic and metabolic profiles in aging animals. We found significant differences
in the body weight of animals up to 6 weeks of the study. However, we found a difference in the
microbial diversity of the group treated with original bacterial strain IL1403 compared to other
groups. Further we found little evidence of reduction in the ratio of firmicutes/bacteroidetes among
the treatment group of animals, an indicator of oxidative stress among aged animals. In proteomic
analysis, we able to express the number of proteins either upregulated or downregulated which play
a crucial role in the pathophysiology of the different ailments and can target specific proteins for
the diagnosis and treatment of degenerative disease. Through metabolite analysis, we are able to
quantify the metabolites such as GABA and Glutamic Acid from the faecal sample after the
treatment with bacterial strains but there is little significant result came.
Keywords: Aging, GABA, Probiotics, Microbial diversity, Proteomics, Metabolites |